Full house in Jaki and beyond session. S Cohen presented fenebrutinib a BTK inhibitor at doses including 200 mg bid is in TNFI-IR or Mtx-IR active pts with RA in a Phase II RCT. 12 week data were similar to adalimumab. New pathway for RA Rx maybe #OP0025 https://t.co/avLSopLju6